Evidence map›Paper›PMID 37280712›Full record

ArticleChinese medicine2023

Integration of transcriptomics and proteomics to elucidate inhibitory effect and mechanism of rosmarinic acid from Perilla frutescens (L.) Britt. in treating Trichophyton mentagrophytes.

Yang-Ding Xu, Yu-Jie Guo, He-Rong Mao, Zhi-Xiang Xiong, Meng-Yu Luo, Rui-Qi Luo, Shan Lu, Lu Huang, Yi Hong

Open access · goldAbstract read
In one paragraph

Article in Chinese medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Comprehensive Review ofFoods (Basel, Switzerland) · 2025
    Review
  2. Article
  3. D-Limonene InhibitsMolecules (Basel, Switzerland) · 2024
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yang-Ding Xu *School of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China.
Yu-Jie Guo *School of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China.
He-Rong MaoInternational Center for TCM Communication Studies, Hubei University of Chinese Medicine, Wuhan, 430065, China.
Zhi-Xiang XiongSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China.
Meng-Yu LuoSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China.
Rui-Qi LuoSchool of Foreign Languages, Hubei University of Chinese Medicine, Wuhan, 430065, China.
Shan LuSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China.
Lu HuangGuangzhou Wellhealth Bio-Pharmaceutical CO., Ltd, Guangzhou, 510200, China. 47153437@qq.com.
Yi HongSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China. hongyiwh@sina.com.
Hubei University of Chinese Medicine · CN

Funding

Hubei University of Chinese Medicine "Construction of graduate student innovation base (Graduate Workstation of Guangzhou Wellhealth Bio-Pharmaceutical Co.,Ltd.)" Project [2022]125Science and Technology Project of Hubei Provincial Department of Education for Young and Middle-aged scientists Q20222009
6 · The paper itself

Abstract

backgroundDermatophyte caused by Trichophyton mentagrophytes is a global disease with a growing prevalence that is difficult to cure. Perilla frutescens (L.) Britt. is an edible and medicinal plant. Ancient books of Traditional Chinese Medicine and modern pharmacological studies have shown that it has potential anti-fungi activity. This is the first study to explore the inhibitory effects of compounds from P. frutescens on Trichophyton mentagrophytes and its mechanism of action coupled with the antifungal activity in vitro from network pharmacology, transcriptomics and proteomics.

methodsFive most potential inhibitory compounds against fungi in P. frutescens was screened with network pharmacology. The antifungal activity of the candidates was detected by a broth microdilution method. Through in vitro antifungal assays screening the compound with efficacy, transcriptomics and proteomics were performed to investigate the pharmacological mechanisms of the effective compound against Trichophyton mentagrophytes. Furthermore, the real-time polymerase chain reaction (PCR) was applied to verify the expression of genes.

resultsThe top five potential antifungal compounds in P. frutescens screened by network pharmacology are: progesterone, luteolin, apigenin, ursolic acid and rosmarinic acid. In vitro antifungal assays showed that rosmarinic acid had a favorable inhibitory effect on fungi. The transcriptomic findings exhibited that the differentially expressed genes of fungus after rosmarinic acid intervention were mainly enriched in the carbon metabolism pathway, while the proteomic findings suggested that rosmarinic acid could inhibit the average growth of Trichophyton mentagrophytes by interfering with the expression of enolase in the glycolysis pathway. Comparison of real-time PCR and transcriptomics results showed that the trends of gene expression in glycolytic, carbon metabolism and glutathione metabolic pathways were identical. The binding modes and interactions between rosmarinic acid and enolase were preliminary explored by molecular docking analysis.

conclusionThe key findings of the present study manifested that rosmarinic acid, a medicinal compound extracted from P. frutescens, had pharmacological activity in inhibiting the growth of Trichophyton mentagrophytes by affecting its enolase expression to reduce metabolism. Rosmarinic acid is expected to be an efficacious product for prevention and treatment of dermatophytes.

Indexed as

EnolasePerilla frutescensProteomicsRosmarinic acidTranscriptomicsTrichophyton mentagrophytes

Identifiers

PMID37280712
PMCPMC10245427
OpenAlexW4379537173

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.